▾ G11 Media Network: | ChannelCity | ImpresaCity | SecurityOpenLab | Italian Channel Awards | Italian Project Awards | Italian Security Awards | ...
InnovationOpenLab

SaponiQx, Probius, and Ginkgo Bioworks Unite to Revolutionize Vaccine Adjuvant Development

SaponiQx, a leader in saponin-based adjuvant discovery, is pleased to announce a strategic collaboration with Probius, a pioneer in quantum molecular spectroscopy for AI-driven discovery, and Ginkgo B...

Business Wire

Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats

LEXINGTON, Mass. & FREMONT, Calif.: SaponiQx, a leader in saponin-based adjuvant discovery, is pleased to announce a strategic collaboration with Probius, a pioneer in quantum molecular spectroscopy for AI-driven discovery, and Ginkgo Bioworks. This partnership, fully funded by the Defense Threat Reduction Agency’s (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD) Program, aims to accelerate the discovery and development of next-generation vaccine adjuvants to combat emerging viral, bacterial, and fungal threats.

The collaboration will integrate Probius’s proprietary Quantum Electrochemical Spectroscopy (QES) molecule characterization technology, which provides unique insights into the molecular physics of complex saponins, to enhance SaponiQx's innovative adjuvant development platform. By integrating QES with high-throughput empirical biological and traditional physicochemical data, the team aims to mathematically represent complex saponins to train Generative Molecular Design AI algorithms, leading to the rapid identification of superior adjuvants.

“Teaming up with Probius and Ginkgo Bioworks represents a pivotal moment in our mission,” said Rebecca Kurnat, Head of Operations at SaponiQx. “With Probius' cutting-edge technology, we are poised to deliver advanced capabilities to the warfighter and respond effectively to the challenges posed by emerging pathogens.”

QES functions as a universal molecular encoder, capturing detailed physics information that traditional methods cannot provide. QES structural signatures enable new in-silico correlations between saponin structures and biochemical outcomes, redefining the landscape of adjuvant discovery.

“Probius is excited to contribute our transformative QES technology to this collaboration,” said John Baldoni, PhD, Chief Scientific Officer at Probius. “By overcoming the limitations of traditional molecular encoders, we are unlocking new possibilities in adjuvant development that can significantly advance SaponiQx and Ginkgo Bioworks in their quest to deliver new adjuvants to the warfighter.”

With the proven success of Agenus' QS-21 Stimulon platform in currently approved vaccines for Shingles, Malaria, and RSV, this collaboration is set to pave the way for the rapid discovery and manufacturing of next-generation adjuvants. These innovative molecules are expected to meet the challenges posed by new and emerging pathogens in vaccine development, by improving the efficacy and durability of vaccines and thus ensuring our preparedness in the face of evolving biological threats.

About SaponiQx

Founded in 2021, SaponiQx, a subsidiary of Agenus Inc., stands at the forefront of saponin-based adjuvant discovery and manufacturing. Its mission is to provide scalable and affordable vaccine adjuvants to enhance global health. Its proprietary adjuvant, STIMULON™ QS-21, forms an integral part of the AS01 adjuvant used in several leading vaccines.

About Probius

Probius, headquartered in Fremont, CA, is a deep-tech company leveraging its proprietary technology to bridge the data gap between biology and AI, illuminating new opportunities for biomedical research and healthcare. By combining physics, mathematics, and biological data, the company is ushering in a new age of AI-enabled biological research and decentralized predictive healthcare. Built on ten years of R&D with over $15M in DoD and investor support, Probius is now commercializing its revolutionary platform.

Forward-Looking Statements of SaponiQx

This press release includes forward-looking statements, subject to risks and uncertainties, concerning the development of vaccines and adjuvants. Refer to the Risk Factors in Agenus’ latest Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the SEC for a detailed discussion of these risks.

Fonte: Business Wire

If you liked this article and want to stay up to date with news from InnovationOpenLab.com subscribe to ours Free newsletter.

Related news

Last News

RSA at Cybertech Europe 2024

Alaa Abdul Nabi, Vice President, Sales International at RSA presents the innovations the vendor brings to Cybertech as part of a passwordless vision for…

Italian Security Awards 2024: G11 Media honours the best of Italian cybersecurity

G11 Media's SecurityOpenLab magazine rewards excellence in cybersecurity: the best vendors based on user votes

How Austria is making its AI ecosystem grow

Always keeping an European perspective, Austria has developed a thriving AI ecosystem that now can attract talents and companies from other countries

Sparkle and Telsy test Quantum Key Distribution in practice

Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…

Most read

Synapse ITS Appoints Josh LittleSun as Chief Technology Officer to Drive…

#PressRelease--Synapse ITS (“Synapse”), a leader in transportation safety, is pleased to announce the appointment of Josh LittleSun as its new Chief Technology…

Rocket Lab Launches Next Batch of Satellites for Kinéis Constellation

$RKLB--Rocket Lab USA, Inc. (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a global leader in launch services and space systems, today successfully launched…

ADTRAN Holdings, Inc. to release fourth quarter 2024 financial results…

#Adtran--ADTRAN Holdings, Inc. (NASDAQ: ADTN) announced today that the Company will release its financial results for the fourth quarter 2024 after market…

AO Mainnet Launches, Ushering in a New Era of Decentralized Computing…

AO, a revolutionary platform for decentralized computing, launches its mainnet today following a highly successful testnet phase, with key milestones…

Newsletter signup

Join our mailing list to get weekly updates delivered to your inbox.

Sign me up!